Advances in Heart Failure - Is It Time to Redefine Patient Selection for Sodium-Glucose Co-transporter 2 Inhibitors?
Published: 09 October 2020
16m 28sPart 4 Q&A Discussion
9m 33sPart 1 SGLT2s as a Heart Failure Drug – How Did We Get Here? Martin R Cowie
10m 1sPart 2 Emerging Data SGLT2 Inhibitors in Heart Failure Faiez Zannad
This educational symposium was originally broadcast as part of the ESC 2020 Digital Congress.
The programme focuses on summarising recent data on SGLT2 inhibitors showing reductions in CV risk, HF hospitalisations and mortality, as well as improved quality-of-life. The expert panel also discuss how these agents should be introduced into clinical practice and contemporary heart failure guidelines for both diabetics and non-diabetics.
- Discuss Current SGLT2 Data and Guideline Recommendations for Utilization in Heart Failure
- Evaluate Emerging Data on the Treatment of Heart Failure with SGLT2 Inhibitors
- Understand the Implications of Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors
More from this programme
SGLT2s as a Heart Failure Drug – How Did We Get Here?
Emerging Data SGLT2 Inhibitors in Heart Failure
Guidelines and Practice Implications
Follow-up Peer-to Peer Discussion
Professor of Medicine
Dr Sanjay Kaul is a Cardiologist at the Cedars-Sinai Medical Center, US where he is also a Professor of Medicine. Dr Kaul received his medical training at the Government Medical College of the University of Kashmir in India.
Dr Kaul is a Fellow of the American Heart Association Councils on Circulation and Arteriosclerosis and Thrombosis, and a Fellow of the American College of Cardiology.
Dr Kaul’s clinical interests are in preventive cardiovascular medicine, diabetes, coronary artery disease. His research interests lie in the fields of acute coronary syndromes, clinical trial and statistical methodology and evidence-based medicine.